Printer Friendly

Research and Markets: Coronary Artery Disease (CAD) - Pipeline Review, H1 2012.

DUBLIN -- Research and Markets ( has announced the addition of Global Markets Direct's new report "Coronary Artery Disease (CAD) - Pipeline Review, H1 2012" to their offering.

Global Markets Direct's, 'Coronary Artery Disease (CAD) - Pipeline Review, H1 2012', provides an overview of the Coronary Artery Disease (CAD) therapeutic pipeline. This report provides information on the therapeutic development for Coronary Artery Disease (CAD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD). 'Coronary Artery Disease (CAD) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Coronary Artery Disease (CAD).

- A review of the Coronary Artery Disease (CAD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Coronary Artery Disease (CAD) pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) pipeline depth and focus of Coronary Artery Disease (CAD) therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit

Source: Global Markets Direct
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 18, 2012
Previous Article:Media Temple and Virb Announce Expanded Partnership to Provide Customers with Comprehensive Site Building, Hosting, and Domain Services.
Next Article:IAM Members Ratify New Contract at Alaska Airlines.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters